Search

everythinglearnresearchcommunity

for

Search:↓

Corticosteroid pulse therapy is more effective for severe alopecia areata than combination therapy.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Baricitinib is effective as a treatment for severe hair loss.

Combining platelet-rich plasma and minoxidil can effectively regrow hair in severe alopecia areata cases.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.

Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.

Baricitinib shows promise in treating severe hair loss.

High-resolution MRI can distinguish between tertiary androgenetic alopecia and severe alopecia areata by measuring scalp and tissue thickness and hair follicle depth.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Zinc supplements may be needed to treat hair loss in hypothyroidism.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Combining high-dose corticosteroids with methotrexate may be effective and safe for severe alopecia areata.

The combined therapy was effective and safe for children with severe alopecia areata.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

The combination of cyclosporine and PUVA might help treat severe alopecia areata.